It is also unknown how the tumor may change across HER2-targeted therapies: one study of the combination of trastuzumab and lapatinib suggested that a change in intrinsic subtype to normal-like after a short course of HER2-targeted therapy might predict pCR30 and that, with the combination of HER2-targeted therapy and endocrine therapy, HR+ /HER2+ tumors frequently converted to the luminal A subtype35. The gene discussed is ERBB2; the disease is neoplasm.